Jan 02, 2024 7:05am EST Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
Nov 13, 2023 7:05am EST Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 06, 2023 7:05am EST Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
Oct 12, 2023 7:05am EDT Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
Sep 12, 2023 7:05am EDT Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
Aug 10, 2023 7:05am EDT Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Aug 09, 2023 7:05am EDT Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
Aug 03, 2023 4:05pm EDT Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023